Basilea | BiotechTV

top of page

Basilea, a profitable anti-infectives company, today landed a contract with BARDA worth up to $268M to develop antifungals and antibiotics

CEO David Veitch describes the news and expands on the success of Basilea's business model.

Company News

Sep 19, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page

Basilea, a profitable anti-infectives company, today landed a contract with BARDA worth up to $268M to develop antifungals and antibiotics

Follow BiotechTV

Sponsors

Sponsor Spotlight